Hypothesis-Generating Brief: Spermidine supplementation

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the inconsistent source-count framing in the Findings Map table, abstract, and Scope (direct/adjacent/mechanistic split and per-class n) against the actual admitted sources enumerated in the bundle
2. Reclassify or re-label the 'immune and inflammation positive signal' as a combination-product signal, not a spermidine-monotherapy signal; add a single sentence in the Findings Map table and Results Summary flagging that the 2/3 positive sources include one combination-product RCT and one preclinical GWI mouse model (Trivedi 2026 is a mouse model, not human)
3. Expand the Tensions and Gaps section to enumerate the specific within- and between-source disagreements by name (Senekowitsch 2023 vs Rhodes 2024; Felix 2024 vs Alsaleh 2026; He 2025 negative vs Xu 2022 positive; Sanayama 2023 higher spermidine in sarcopenia vs the broader pro-spermidine mechanistic literature; SPERMIDINE TOXICITY 2022 vs the broader longevity literature), with the specific direction and population for each
4. Verify and align author-year prose citations (Wirth 2018 vs Wirth 2019, He 2025, Yang 2024, Iorio-Siciliano 2024, Choi 2026, Yuan 2021, Saiyed 2026) against bundle entries; add any cited author not present in the bundle or remove the citation
5. Reconcile the 'no p-values reported' characterization of Keohane 2024 with the abstract's count of 1250 extractable claims; clarify in the body that 'effect direction null' is a structured-extraction field and is distinct from statistical null
6. Either add Cruz-Jentoft 2019 and Ioannidis 2005 to the source bundle if they are being cited as evidentiary support, or reframe them in the Limitations section as external methodological context rather than corpus sources
7. Enumerate the 3 additional search queries inline in the Search Summary rather than referring the reader to a supplementary file
8. Place the 'Autophagy-Enhancers to Reduce Sleep' (R33) protocol explicitly in the Findings Map (e.g., as a contextual adjacent entry) or document its exclusion

Major issues

• The manuscript conflates the primary clinical RCT Felix 2024, which tested a combination product (AM3 150 mg + spermidine 0.6 mg + hesperidin 50 mg), with a claim about spermidine-specific immune/inflammation effects; the dose of spermidine is too low to isolate its contribution, and the synthesis does not adequately correct the 'positive signal' framing in the Findings Map table or Results Summary
• Findings Map table and Results Summary are internally inconsistent: the Findings Map lists 4 mechanistic or model-system sources and 5 direct clinical sources (33 adjacent clinical implied), while the Scope and abstract say 5 direct, 33 adjacent, 4 mechanistic — these numbers should be reconciled and the outcome-class totals (n=3 for Immune and Inflammation but abstract only highlights this positive class) cross-checked against the source bundle
• Several cited author-year references (e.g. 'Wirth 2018', 'Wirth 2019', 'He 2025', 'Yang 2024', 'Iorio-Siciliano 2024', 'Choi 2026', 'Yuan 2021', 'Saiyed 2026') do not have bundle entries under those exact cited_as labels — the Wirth 2019 protocol and Wirth 2018 RCT appear as separate entries but the prose does not consistently distinguish them, and the 'Improving Vaccination in Older 2023' and 'Metabolic Responses to Spermidine 2023' entries are described as uniformly 'protocol or review-stage material without reported p-values' without confirming they are not in the admitted source set vs. only in contextual adjacent
• The Tensions and Gaps section is thin and generic — it lists only a high-level methodological recommendation rather than surfacing the specific, named disagreements identified in the body (Senekowitsch 2023 vs Rhodes 2024; Felix 2024 positive vs Alsaleh 2026 null; Nayak 2020 vs SPERMIDINE TOXICITY 2022; He 2025 negative vs Xu 2022 positive); the abstract claims 206 cross-study disagreements but the Tensions section does not enumerate them

Minor issues

• Several null-finding sources (Keohane 2024, Senekowitsch 2023) are framed as 'no p-values reported' in the body, which conflicts with the search summary's claim of extractable quantitative findings; this should be reconciled or the null classification should be footnoted as effect-direction null rather than statistical null
• The 'Bruno 2025' entry has null DOI in the bundle but is referenced in the findings map as adjacent clinical; this should be flagged or corrected
• The Longevity section's integrative inference that Nayak 2020 is 'consistent with' the yeast mitochondrial-deficiency toxicity model is presented as an integrative read but is itself a synthesis claim that should be more clearly hedged
• The Limitations section cites 'Cruz-Jentoft 2019 (27 kg grip strength for men, 16 kg for women)' and 'Ioannidis 2005' as if they are corpus sources, but neither appears in the source bundle — these need to be either added to the bundle or reframed as external context citations
• The Schirwarz 2018/2022 and Wirth 2018/2019 author-year pairing is confusing; the synthesis should explicitly disambiguate by first-author and year whenever these adjacent RCTs are co-cited
• Search summary claims '(... 3 additional queries; see methods_pack.json ...)' which is not auditable in the manuscript itself; at minimum the additional queries should be enumerated inline
• The 'Autophagy-Enhancers to Reduce Sleep' protocol (R33) is not mapped to any outcome class in the Findings Map despite being a registered spermidine RCT — should be placed or explicitly excluded

Reviewer note

This evidence map of spermidine supplementation is largely well-structured and faithfully maps a heterogeneous 42-source corpus across 11 outcome classes, with explicit per-class signal directions, source counts, and directness flags. The framing as a 'tiered evidence profile' is appropriate for the article type and the manuscript generally does not collapse the landscape into a single causal or clinical claim. Source attribution is broad and the body text traces each per-class finding to named studies. However, several issues prevent an accept: (1) The 'positive signal' classification for the immune and inflammation class rests on Felix 2024 (a 0.6 mg spermidine combination product with AM3 and hesperidin — dose too low to isolate spermidine) and Trivedi 2026 (a mouse GWI model, not human), so the column is mis-labeled as a human positive signal; (2) The Tensions and Gaps section is generic and does not surface the specific named disagreements the body has already identified, which is the principal value-add of an evidence map; (3) Source-count framing is internally inconsistent between the abstract, Scope, and Findings Map table; (4) Several cited author-year references are not cleanly traceable to bundle entries; (5) The Limitations section cites Cruz-Jentoft 2019 and Ioannidis 2005 as if they are corpus sources but neither is in the bundle. These are bounded fixes — the evidence map's overall architecture, per-class decomposition, and source-attribution discipline are sound. A revise is warranted to correct the immune/inflammation mislabeling, expand Tensions and Gaps with the specific disagreements, reconcile source counts, and tidy author-year citations.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis